ClinicalTrials.gg
CompletedNCT01273246Updated Jul 28, 2021

Safety of an Inactivated Enterovirus Type 71 Vaccines in Healthy Children

A Phase 1 interventional study of 100U inactivated Enterovirus Type 71 Vaccine and 200U inactivated Enterovirus Type 71 Vaccine in Hand-foot-mouth Disease and Infection; Viral, Enterovirus, sponsored by Sinovac Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 6 Months to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-28.

Sponsored by Sinovac Biotech Co., Ltd · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
6 Months to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd — 4 open to participants now, 4 under way, 2 of them phase 3. Hand, Foot and Mouth Disease · Sinovac Biotech Co., Ltd.

Enrollment
14th of 15
132 · median 744
Started
2011
the only one that year
Phase 1
Only one
of the 20
Registered
1st of 20
by date

Among the 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd, this one is the 14th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2011, is the only one in phase 1, and was the 1st registered.

Hand, Foot and Mouth Disease

59 studies on the registry are indexed under Hand, Foot and Mouth Disease; 10 are open to participants now.

Browse Hand, Foot and Mouth Disease studies →

Open to participants now

4 of the 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 4 Hand, Foot and Mouth Disease studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 6 Months to 11 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd, or all of them as a file.
02

Study summary

A Phase I clinical trialto evaluate the safety of an Inactivated Enterovirus Type 71 Vaccine in healthy children (3-11y) and infants (6-35m).

Read the detailed description

36 eligible children aged from 3 to 11 years and 96 eligible infants aged from 6 to 35 months will be enrolled in the study, they will be randomized to receive different dosage of vaccine candidate or placebo to evaluate the safety of this vaccine

03

Conditions studied

  • Hand-foot-mouth Disease
  • Infection; Viral, Enterovirus
04

Who can participate

Ages eligible
6 Months to 11 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males and females, aged from 6 months to 11 years old Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator
  2. Provided legal identification for the sake of recruitment.
  3. Subjects and/or parent(s)/legal guardian(s) are able to understand and sign informed consents.
  4. Birth weight more than 2500 grams

Exclusion criteria

Exclusion Criteria:

  1. Histroy of Hand-foot-mouth Disease
  2. Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine
  3. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
  4. Congenital malformations or developmental disorders, genetic defects, or severe malnutrition
  5. Epilepsy, seizures or convulsions history, or family history of mental illness
  6. disease or immunodeficiency, or parents, brothers and sisters have autoimmune diseases or immunodeficiency
  7. History of asthma, angioedema, diabetes or
  8. History of thyroidectomy or thyroid disease that required medication within the past 12 months
  9. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
  10. Asplenia, functional asplenia or any condition resulting in the absence or removal the spleen
  11. Acute illness or acute exacerbation of chronic disease within the past 7 days
  12. Any history of medications or cytotoxic medications or inhaled within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
  13. History of any blood products within 3 months
  14. Administration of any within 28 days
  15. Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or allergy treatment within 14 days
  16. Axillary temperature > 37.0 centigrade before vaccination
  17. Abnormal laboratory parameters before vaccination
  18. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a to protocol participation or impairs a volunteer's ability to give
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    Children Group 1: 200U EV71 vaccine

    12 children received 3 doses of 200U EV71 vaccine 28 days apart

    Biological: 200U inactivated Enterovirus Type 71 Vaccine

  • Placebo comparator
    Children Group 1: Placebo

    6 children received 3 doses of placebo 28 days apart

    Biological: Placebo

  • Experimental
    Children Group 2: 400U EV71 vaccine

    12 children received 3 doses of 400U EV71 vaccine 28 days apart

    Biological: 400U inactivated Enterovirus Type 71 Vaccine

  • Placebo comparator
    Children Group 2: Placebo

    6 children received 3 doses of placebo 28 days apart

    Biological: Placebo

  • Experimental
    Infants Group 1: 100U EV71 vaccine

    24 infants received 3 doses of 100U EV71 vaccine 28 days apart

    Biological: 100U inactivated Enterovirus Type 71 Vaccine

  • Placebo comparator
    Infants Group 1: Placebo

    8 infants received 3 doses of placebo 28 days apart

    Biological: Placebo

  • Experimental
    Infants Group 2: 200U EV71 vaccine

    24 infants received 3 doses of 200U EV71 vaccine 28 days apart

    Biological: 200U inactivated Enterovirus Type 71 Vaccine

  • Placebo comparator
    Infants Group 2: Placebo

    8 infants received 3 doses of placebo 28 days apart

    Biological: Placebo

  • Experimental
    Infants Group 3: 400U EV71 vaccine

    24 infants received 3 doses of 400U EV71 vaccine 28 days apart

    Biological: 400U inactivated Enterovirus Type 71 Vaccine

  • Placebo comparator
    Infants Group 3: Placebo

    8 infants received 3 doses of placebo 28 days apart

    Biological: Placebo

Interventions

  • Inactivated Enterovirus Type 71 Vaccine, 100U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm

    Also known as: EV71 vaccine

  • Inactivated Enterovirus Type 71 Vaccine, 200U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm

    Also known as: EV71 vaccine

  • Inactivated Enterovirus Type 71 Vaccine, 400U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm

    Also known as: EV71 vaccine

  • BiologicalPlacebo

    Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm

06

What researchers measure

Primary outcomes

  1. To evaluate the safety of the inactivated Enterovirus Type 71 Vaccine

    All adverse events were records. Blood cell and biochemistry were performed.

    Time frame: 6 months

Secondary outcomes

  1. To evaluate the immunogenicity of the inactivated Enterovirus Type 71 Vaccine

    virus neutralization assays were performed.

    Time frame: 6 months

07

Study locations

1 site
  • GuangXi Center for Diseases Control and Prevention
    Nanning, Guangxi, China
08

References and documents

Publications

  • Mao Q, Cheng T, Zhu F, Li J, Wang Y, Li Y, Gao F, Yang L, Yao X, Shao J, Xia N, Liang Z, Wang J. The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children. PLoS One. 2013 Nov 19;8(11):e79599. doi: 10.1371/journal.pone.0079599. eCollection 2013. PubMed 24260259 ↗
  • Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, Liu Y, Yin WD, Li RC, Wang JZ. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine. 2012 May 9;30(22):3295-303. doi: 10.1016/j.vaccine.2012.03.010. Epub 2012 Mar 15. PubMed 22426327 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Jun 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2011
First posted
Jan 10, 2011
Start
Jan 2011
Primary completionActual
Jun 2011
CompletionActual
Jul 2011
Last update
Jul 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01273246
Responsible party
Sponsor
First posted
Jan 10, 2011
Start date
Jan 2011
Primary completion
Jun 2011
Completion
Jul 2011
Last update
Jul 28, 2021

Study contacts

Yan-pin Li, MD
principal investigator · Guangxi Centers for Disease Control and Prevention

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enterovirus 71 vaccine

Start the discussion